阿根廷婴儿呼吸道合胞病毒(RSV)预防策略的潜在影响与成本效果评估
该研究采用静态比例结局模型,评估阿根廷2025—2034年婴儿使用长效单克隆抗体或母体RSV疫苗(全年或季节性接种)相对于无药物干预的成本效果。两种策略均可预防>25%的5岁以下RSV死亡和约30%的6月龄以下RSV死亡;剂量价格为50美元时,两者成本效果概率均为100%,季节性策略可改善成本效果约45%。
要点
- RSV单克隆抗体或母体疫苗均可预防>25%的5岁以下RSV死亡和约30%的6月龄以下RSV死亡。
- 剂量价格50美元时,两种产品相对于无干预的成本效果概率均为100%。
- 六个月的季节性策略可达到相似健康影响,并改善成本效果约45%(假设剂量价格不变)。
核心结论
- 在阿根廷,当每剂价格≤50美元时,RSV单克隆抗体或母体RSV疫苗均值得考虑。
- 季节性策略可改善成本效果。
研究设计与样本
- 研究使用静态比例结局模型,计算阿根廷2025—2034年十年期间使用RSV单克隆抗体或母体RSV疫苗(假设全年和季节性接种)的成本和后果。
- 每种干预均与无药物RSV干预进行比较。
- 主要结局为从社会角度计算的每避免一个伤残调整生命年(DALY)的贴现成本。
- 假设支付意愿为每避免一个DALY 12,285美元(全国人均国内生产总值的0.9倍)。
- 使用关于成本和疾病负担的人群研究数据以及两种干预临床试验的效力作为输入,并进行了确定性和概率不确定性分析。
主要发现
- 任一种策略(RSV单克隆抗体或母体RSV疫苗)均可预防>25%的5岁以下RSV死亡和约30%的6月龄以下RSV死亡(6月龄以下是大多数干预影响发生的年龄组)。
- 剂量价格为50美元时,两种产品相对于无干预的成本效果概率均为100%:全年使用RSV单克隆抗体每避免一个DALY的成本为5,283美元(95%CI 5,203—5,363),母体RSV疫苗为5,522美元(95%CI 5,427—5,617)。
- 六个月的季节性策略可达到相似的健康影响,并可在假设剂量价格不变的情况下改善成本效果约45%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: New interventions are available for the prevention of respiratory syncytial virus (RSV) disease in young infants. We aimed to assess the potential impact and cost-effectiveness of using a long-acting monoclonal antibody (RSV mAb) or maternal RSV vaccine in the Argentine context. METHODS: We used a static proportionate outcomes model to calculate the costs and consequences of using RSV mAb or maternal RSV vaccine over a ten-year period (2025-2034) in Argentina, assuming both year-round and seasonal administration. We compared each intervention to no pharmaceutical RSV intervention. The primary outcome was the discounted cost per disability-adjusted life year (DALY) averted from a societal perspective. We assumed willingness-to-pay of US$ 12,285 per DALY averted (0.9 times the national gross domestic product per capita). We used population study data on costs and disease burden and the efficacy of clinical trials of both interventions as inputs. We ran deterministic and probabilistic uncertainty analyses. FINDINGS: Either strategy (RSV mAb or maternal RSV vaccine) could prevent >25% of RSV deaths aged <5 years and ∼30% aged <6 months (the age group where most intervention impact occurs). With a dose price of $US 50, both products have a 100% probability of being cost-effective compared to no intervention (US$ 5283 [95%CI $5203-$5363] and US$ 5522 [95%CI $5427 - $5617] per DALY averted for year-round use of RSV mAb and maternal RSV vaccine, respectively). Similar health impact could be achieved by a six-month seasonal strategy, which could improve cost-effectiveness by around 45% (assuming the dose price is unchanged). INTERPRETATION: Either RSV mAb or maternal RSV vaccine are worth consideration in Argentina when priced at ≤US$ 50 per dose. A seasonal strategy could improve cost-effectiveness.
引用
- Guiñazú G, Dvorkin J, Mahmud S, et al. Evaluation of the potential impact and cost-effectiveness of respiratory syncytial virus (RSV) prevention strategies for infants in Argentina. Vaccine. 2024. PMID: 39154512. doi:10.1016/j.vaccine.2024.126234
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。